
Profitability, historical returns, and peer comparisons.
According to Immunome, Inc.’s latest financial reports and current stock price. The company's current ROE is -50.56%. This represents a change of 262.04% compared to the average of -13.97% of the last 4 quarters.
The mean historical ROE of Immunome, Inc. over the last ten years is -67.44%. The current -50.56% ROE has changed -25.03% with respect to the historical average. Over the past ten years (40 quarters), IMNM's ROE was at its highest in in the September 2020 quarter at 17.07%. The ROE was at its lowest in in the March 2019 quarter at -103.66%.
Average
-67.44%
Median
-47.21%
Minimum
-221.56%
Maximum
31.12%
Discovering the peaks and valleys of Immunome, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 332.02%
Maximum Annual ROE = 31.12%
Minimum Annual Increase = -245.70%
Minimum Annual ROE = -221.56%
| Year | ROE | Change |
|---|---|---|
| 2025 | -33.48% | -79.29% |
| 2024 | -161.71% | 81.51% |
| 2023 | -89.09% | -59.79% |
| 2022 | -221.56% | 332.02% |
| 2021 | -51.28% | 18.87% |
| 2020 | -43.14% | -245.70% |
| 2019 | 29.61% | -4.87% |
The current ROE of Immunome, Inc. (IMNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-94.76%
5-year avg
-111.43%
10-year avg
-67.44%
Immunome, Inc.’s ROE is greater than MacroGenics, Inc. (-31.27%), greater than Immunocore Holdings plc (-2.35%), greater than ArriVent BioPharma, Inc. (-50.26%), greater than Immatics N.V. (-47.04%), greater than SELLAS Life Sciences Group, Inc. (-35.91%), greater than Celldex Therapeutics, Inc. (-52.36%), less than Sutro Biopharma, Inc. (185.30%), greater than Bicycle Therapeutics plc (-33.22%), greater than Immix Biopharma, Inc. (-38.44%), greater than Corvus Pharmaceuticals, Inc. (-36.15%),
| Company | ROE | Market cap |
|---|---|---|
| -31.27% | $231.23M | |
| -2.35% | $1.62B | |
| -50.26% | $946.71M | |
| -47.04% | $1.13B | |
| -35.91% | $2.29B | |
| -52.36% | $2.27B | |
| 185.30% | $170.62M | |
| -33.22% | $254.12M | |
| -38.44% | $692.24M | |
| -36.15% | $895.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunome, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immunome, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Immunome, Inc.'s ROE?
How is the ROE calculated for Immunome, Inc. (IMNM)?
What is the highest ROE for Immunome, Inc. (IMNM)?
What is the 3-year average ROE for Immunome, Inc. (IMNM)?
What is the 5-year average ROE for Immunome, Inc. (IMNM)?
How does the current ROE for Immunome, Inc. (IMNM) compare to its historical average?